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Introduction
　SAMHD1 (1-626 aa), composed of a tandemly linked-
SAM domain (45-110 aa) and HD domain (164-319 aa), has 
recently been identified as a restriction factor against HIV-
1. SAMHD1 was originally identified as a human homolog 
of mouse Mg11 isolated from IFNγ-stimulated mouse den-
dritic cells [1,2], suggesting that SAMHD1 is an IFN-stim-
ulated gene [3,4] though it depends on cell-type [3,5].
　In parallel to the hosts obtaining restriction factors, vi-
ruses have developed mechanisms to overcome these re-
striction factors. Vpx, encoded by HIV-2 and simian immu-
nodeficiency viruses (SIVs) but not by HIV-1 [6,7,8,9,10], is 
a potent counterpart of SAMHD1. These Vpx proteins bind 
to the SAMHD1 C-terminal motif (606-626 aa) and deliver 
the complex to the CRL4DCAF1 ubiquitin E3 ligase [11] for 
subsequent proteasome-dependent degradation. 
　HD domain contains a catalytic core for hydrolysis activity 
and the several reports showed that the HD domain-containing 
C-terminal region of SAMHD1 (120-626 aa) inhibits HIV-1 
reverse transcription (RT) by its dGTP dependent deoxynu-
cleoside triphosphate-triphosphatase (dGTP triphosphatase) 
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activity [12,13]. In addition, recombinant SAMHD1 protein 
possesses 3ʼ to 5ʼ exonuclease activities against DNAs and 
RNAs, as well as nucleic acids and viral genome binding 
abilities in which the SAM domain containing N-terminal 
region (1-118 aa) plays a crucial role [14].  
　Interestingly, various cell lines endogenously express the 
SAMHD1 [1,6,7], but SAMHD1 can inhibit HIV-1 infection 
only in terminally differentiated myeloid cells, such as PMA-
differentiated THP-1 [6,9,15], monocyte-derived macrophag-
es (MDMs) [13] and monocyte-derived dendritic cells (MD-
DCs) [6,7,13], and resting CD4+ T cells [8,16] but not in 
undifferentiated THP-1 and HEK293T cells [7]. Exogenous-
ly over-expressed SAMHD1 restricted the infection in 
PMA-differentiated U937 macrophage cells but not in un-
differentiated U937 and HeLa cells [3]. Thus, there are un-
known mechanism(s) contributing to the cell type-specific 
HIV-1 restriction by SAMHD1. 
　Meanwhile, the protection of innate immunity-associated 
proteins from ubiquitination and degradation, i.e., protein 
stabilization, is one of the mechanisms to induce innate im-
mune signaling. For example, Lee et al. [17] recently showed 
that the TBK1 protein, a key mediator in type I IFN expres-
sion, is stabilized by CDC37 in IFN-stimulated DNA and 
retrovirus sensing. Korczeniewska et al. [18] showed that 
the COP9 signalosome stabilizes the IFN regulatory factor 
5 (IRF5) protein, an important role player in the induction 
of type I IFNs and proinflammatory cytokines. Thus, pro-
tein stabilization is a critical event in innate immunity. 
　To understand the involvement of SAMHD1 stabilization 
in the SAMHD1-induced cell-type specific HIV-1 infection 
restriction, we analyzed the expression levels and stability 
of the full-length SAMHD1 protein and its deletion mutants 
in U937, TE671, and HeLa cells. We describe supporting 
evidences for SAMHD1 is post-translationally regulated 
and the significance of SAM domain-containing and HD 
domain-containing region for the SAMHD1 protein stability.
Materials and Methods
　Cells. THP-1 and U937 cells were grown in RPMI 
medium (Wako) at 37 °C in a 5% CO2 incubator. HeLa 
and TE671 cells were grown in Dulbeccoʼs modified Eagle 
medium (D-MEM) (Wako). Both media were supplemented 
with 8% heat-inactivated fetal bovine serum (FBS) (PAA 
Laboratories GmbH) and 1 % penicillin-streptomycin (Sig-
ma-Aldrich). Unless indicated, all cells were seeded at 1x106 
cells per 6 cm culture-dish. At 24 hrs after transfection, 
U937 cells were stimulated by phorbol 12-myristate 13-ac-
etate (PMA) at various concentrations, to promote differen-
tiation into macrophages.
Real-time PCR 
　THP-1 cells were seeded in 24-well dishes (1x105/well), 
and total RNA samples were prepared by Trizol Reagent 
(Ambicon) after differentiation with 30, 50, and 500 ng/ml 
PMA for 48 hrs. Semi-quantitative RT-PCR was performed 
with a high fidelity RT-PCR kit (TAKARA). Real-time PCR 
was performed with M-MLV reverse transcriptase (NEB). 
A SYBR Green PCR kit (TOYOBO) was used to quantitate 
the PCR products on the ABI PRISM 7900HT real-time 
PCR detection system. The amounts of the SAMHD1 PCR 
products were normalized by those of the GAPDH PCR 
products. The nucleotide sequences of the primers for the 
SAMHD1 mRNA were 5ʼ-AGCGATTGGTTCAAATCCAC-3ʼ 
and 5ʼ-TCGATTGTGTGAAGCTCCTG-3 ,̓ and for the GAP-
DH mRNA were 5ʼ-GAGTCAACGGATTTGGTCGT-3ʼ and 
5ʼ-TTGATTTTGGAGGGATCTCG-3.̓ 
　Plasmids. The C-terminally HA epitope-tagged full-length 
SAMHD1 (1-626 aa), SAMHD1n (1-119 aa), and SAMHD1c 
(120-626 aa) expression plasmids were constructed by am-
plifying each sequence from the full-length SAMHD1 ex-
pression plasmid (OriGene Technologies), as a template. 
The pcDNA3.1 vector was purchased from Invitrogen. 
　The PCR primers for amplifying the full-length HA-tagged 
SAMHD1 sequence were a forward primer 5ʼ-GTGTAGC-
CATGCAGCGA-3ʼ (SAMHD1 F) and a reverse primer, 
5ʼ-TCATGCGTAATCCGGAACATCGTACGGGTACATT-
GGGTCATCTTTAAAAAGCTG-3ʼ (SAMHD1-HA-R); for 
HA-tagged SAMHD1n sequence, the SAMHD1 F primer 
and a reverse primer, 5ʼ-TCATGCGTAATCCGGAACATCG-
TACGGGTAATTAATTACCTTCATTGTATC-3;̓ and for HA-
tagged SAMHD1c sequence, a forward primer, 5ʼ-GTAGCCA-
TGGATCCTATCCATGGCCAC-3 ,̓ and the SAMHD1-HA-R 
primer. Each PCR product was inserted into the pcDNA3.3-
TOPO vector (Invitrogen). 
　An enhanced green fluorescent protein (EGFP) expression 
plasmid was generated in our laboratory. The EGFP stop 
codon was replaced by an EcoRI sequence in the EGFP ex-
pression plasmid (EGFP-EcoRI). To construct the C-termi-
nally SAMHD1c-fused EGFP expression plasmid (GFP-
HD), the HD region was amplified by PCR, using the 
SAMHD1c-HA expression plasmid as the template, with 
the EcoRI sequence-containing forward primer, 5ʼ-TTATT-
AGAATTCGATCCTATCCATCATCAC-3 ,̓ and the XhoI 
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sequence-containing reverse primer, 5ʼ-TTATTACTCGAGT-
CACATTGGGTCATCTTT-3 .̓ The PCR product was digest-
ed with the EcoRI and XhoI restriction enzymes and insert-
ed into the EGFP-EcoRI plasmid at the EcoRI and XhoI 
sites. 
　The expression plasmid for C-terminally Myc-tagged 
APOBEC3G was a kind gift from Dr. Yasumasa Iwatani 
(National Hospital Organization Nagoya Medical Center, 
Nagoya, Japan) [19]. The Vif expression plasmid was ob-
tained from Dr. Klaus Strebel (National Institutes of Health, 
Bethesda, MD, United States of America) [20], through Dr. 
Yasumasa Iwatani. The N-terminally SAMHD1n-fused 
APOBEC3G expression plasmid (SA3G) was generated as 
follows. The SAMHD1n-SalI sequence was produced by 
PCR with the SAMHD1 F primer and the SalI sequence-
containing reverse primer 5ʼ-CCCGTCGACATTAATTAC-
CTTCAT-3 ,̓ and cloned into the pCR 2.1 TOPO-vector (In-
vitrogen). The SalI-APOBEC3G-Myc plasmid was generated 
by introducing a SalI sequence in frame at the 5ʼ side of the 
start codon of the APOBEC3G-Myc expression plasmid 
with the SalI sequence-containing forward primer, 5ʼ-CTG-
CAGAATGTCGACATGAAGCCTCACTT -3 ,̓ and a reverse 
primer, 5ʼ-AGGCTTCATGTCGACATTCTGCAGATATCC-3 .̓ 
The SAMHD1n-SalI plasmid was digested with the EcoRI 
and SalI restriction enzymes. The SalI-APOBEC3G-Myc 
plasmid was digested with the SalI and Hind III restriction 
enzymes. The Myc-tagged APOBEC3G expression plasmid 
was digested with the EcoRI and Hind III restriction en-
zymes and used as the vector. The EcoRI/SalI-digested 
SAMHD1n fragment, the SalI/Hind III-digested APOBEC3G 
fragment, and the EcoRI/Hind III-digested vector fragment 
were ligated. 
　All plasmids described above are driven by the CMV 
promoter. The nucleotide sequences of the plasmid DNAs 
constructed in this study were confirmed by sequencing 
(Applied Biosystems).
　Transfection. 1x106 cells per 6cm culture-dish was seed-
ed, and incubated at 37 °C in a 5% CO2 incubator for 24 hrs. 
Two μg of plasmid DNA were mixed with 10 μl of FuGENE 
HD transfection reagent (Promega), in 100 μl of D-MEM 
medium without FBS and antibiotics. The transfection mix-
ture was added to the cell supernatant. 
　SDS-PAGE and western blotting analysis. A 10 mM 
MG132 (Sigma) stock solution was prepared in dimethyl 
sulfoxide. At 24 hrs after transfection, the cell culture me-
dium was replaced with fresh medium, and MG132 was 
added to a 5 μM final concentration. Cell lysates were pre-
pared 24 hrs after with 1x sample buffer (10% glycerol, 
1.5% SDS, 0.005% bromophenol blue, 50 mM Tris/HCl, pH 
6.8), and equal quantities of total protein from each sample 
were fractionated by sodium dodecyl sulfate polyacrylam-
ide gel electrophoresis (SDS-PAGE). 
　For western blot (WB) analyses, the proteins were trans-
ferred to a PVDF membrane (Millipore) in a wet blotter 
(Bio-Rad). The membranes were incubated with the corre-
sponding primary antibodies overnight at 4 °C, and then 
incubated with HRP-conjugated anti-mouse IgG (Bio-Rad) 
or with protein G (Bio-Rad) for 1 hr at 4 °C. The primary 
antibody-bound proteins were visualized by enhanced 
chemiluminescence reagents (Bio-Rad). Immunoblotting 
images were captured using Fluor Chem Imaging System 
(IS-8800, Alpha Innotech). The relative intensity levels of 
each protein compared to β-actin were calculated with the 
equation, protein intensity/β-actin protein intensity by using 
Alpha Ease software. 
　Primary antibodies. Monoclonal antibodies against β-actin 
(Santa Cruz Biotechnology), HA (COVANCE), GFP (Nac-
alai Tesque), and Myc (Cell Signaling) were used. The anti-
Vif antibody was obtained through the AIDS Research and 
Reference Reagent Program, NIAID, NIH, from Dr. Mi-
chael H. Malim [21,22]. Polyclonal antibody against human 
SAMHD1 (residues 88-337) was purchased from Protein-
tech (12586-1-AP).
Results
　The SAMHD1 C-terminal HD domain-containing re-
gion is degraded in the proteasome, and the N-terminal 
SAM domain-containing region inhibits the degrada-
tion. THP-1 monocyte and U937 monocyte cells express 
and do not express endogenous SAMHD1 protein, respec-
tively. However, the transduction of U937 cells with SAM-
HD1, followed by the PMA-induced differentiation dramat-
ically restricts the HIV-1 infection similar extent to the 
PMA-differentiated THP-1 cells [6,9,15,23]. Why SAMHD1 
becomes functional as an anti-HIV-1 factor after the PMA-
induced differentiation in monocyte cells? To address this 
query, Lahouassa et al. showed that the expression of exog-
enous SAMHD1 protein was elevated after the PMA-in-
duced differentiation in U937 cells [13]. This led us to spec-
ulate that the SAMHD1 protein level may be regulated at 
certain stage. Thus, we compared the endogenous SAM-
HD1 protein expression in THP-1 cells treated or untreated 
with the PMA stimulation. As shown in Figure 1A, the 
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SAMHD1 protein level was significantly enhanced by PMA 
stimulation in THP-1 cells. To know if these protein expres-
sion levels reflect a quantitative difference of SAMHD1 
mRNA before and after the PMA stimulation, we performed 
the real-time PCR by using specific primers for SAMHD1 
on total RNAs extracted from THP-1 cells treated with dif-
ferent PMA quantity (0, 10, 50, and 500 ng/mL). To our sur-
prise, there was no difference in SAMHD1 mRNA level 
before and after the stimulation, regardless of increased 
quantity of the PMA (Fig. 1B). There are two possible ways 
to regulate protein abundance: post-transcriptional control 
of transcripts and post-translational control of protein. How-
ever, in many cases, protein abundance is post-translation-
ally regulated by proteasomal degradation. In fact, the HD 
region contains many putative ubiquitination sites, as deter-
mined with the CKSAAP_ UbSite program (data not shown). 
Thus, it is highly speculated that endogenous SAMHD1 
protein expression was post-translationally regulated in 
THP-1 cells. 
　We next wanted to identify which domain is responsible 
for the post-translational regulation of SAMHD1. We gener-
ated the C-terminally HA-tagged full-length SAMHD1 (1-
626 aa), the N-terminal SAM domain-containing aa 1-119 
region (SAMHD1n), and the C-terminal HD domain-con-
taining aa 120-626 region (SAMHD1c) expression plasmids 
(Fig. 2A). Each plasmid was transfected into U937 cells and 
the cells were PMA-differentiated. As in undifferentiated 
THP-1 cells, none of the proteins were detected in undif-
ferentiated U937 cells (Fig. 2B lane 1, 3, and 5). In contrary, 
all the proteins were expressed upon the PMA-induced dif-
ferentiation, and the expression levels of the full-length 
SAMHD1 and SAMHD1n proteins were much higher than 
that of the SAMHD1c protein in PMA-differentiated U937 
cells (Fig.2B, lane 2, 4, and 6), leading us to speculate that 
the SAMHD1n stabilizes the SAMHD1 protein in differen-
tiated U937 cells. However, it may simply reflect the PMA 
stimulation-induced protein expression from CMV promot-
er [24]. We had previously searched for various cell lines in 
which SAMHD1 restricts HIV-1 infection without the PMA 
stimulation and, as a result, we found TE671 rhabdomyosar-
coma cells moderately restricted the infection by transiently 
expressed SAMHD1 (manuscript in press). Of note, tran-
siently expressed SAMHD1-mediated HIV-1 infection re-
striction was not observed in HeLa, H292, C33A, and NP2 
(manuscript in press). Thus, in this study, we transfected 
each plasmid into TE671 cells and HeLa cells, the cells in 
which SAMHD1 does and does not restrict the HIV-1 vector 
infection, respectively, and the cells were treated with the 
proteasome inhibitor, MG132. As in PMA-differentiated 
U937 macrophage cells, the SAMHD1c protein was barely 
detected in TE671 cells and in HeLa cells, but the MG132 
treatment significantly enhanced the protein abundances 
(Fig. 2C, lane 5 versus lane 6, and Fig. 3, lane 5 versus lane 
6). These results indicated that the SAMHD1c protein is de-
graded by the proteasome. On the other hand, the amounts 
of the full-length SAMHD1 and SAMHD1n proteins were 
much higher than that of the SAMHD1c protein in TE671 
cells (Fig.2C lane 1, 3, and 5), indicating that the SAMHD1n 
protects the full-length SAMHD1 protein from proteasomal 
degradation induced by SAMHD1c in TE671 cells. These 
former two protein expression levels are not significantly 
affected by the MG132 treatment (Fig. 2C lane 1 versus 2, 
and lane 3 versus 4), In contrary to that observed in TE671 
cells, the amount of full-length protein was much lower than 
SAMHD1n protein in HeLa cells (Fig. 3 lane 1 versus 3), 
indicating that the SAMHD1n-mediated full-length SAM-
HD1 protein stabilization occurs more efficiently in TE671 
cells than in HeLa cells. Moreover, the expression of full-
length SAMHD1 was much higher than the SAMHD1n pro-
tein in U937 macrophage cells compare to that observed in 
TE671 cells (Fig. 2B lane 2 versus 4 and Fig.2C lane 1 ver-
sus 3). Thus, we speculate that the full-length SAMHD1 
Figure 1. The SAMHD1 protein is post-translationally-regulated. 
(A) The endogenous SAMHD1 protein expression was analyzed 
in undifferentiated THP-1 and PMA-differentiated THP-1 cells. 
THP-1 cells were stimulated with 500ng/mL PMA for overnight. 
A WB analysis with a SAMHD1-specific antibody was performed. 
β-actin was detected as a loading control. (B) Real-time PCR for 
quantitation of SAMHD1 mRNA with specific primers were per-
formed on THP-1 cells stimulated with different quantity of PMA. 
Relative quantities of SAMHD1 mRNA to GAPDH mRNA are 
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protein stability may correlate with SAMHD1-mediated HIV-
1 vector infection restriction. Overall, these results suggest-
ed that the SAMHD1n protects the SAMHD1 protein from 
the SAMHD1c -mediated proteasome degradation. 
 
　The SAMHD1 C-terminal region leads to the protea-
some-dependent degradation of a heterologous protein. 
To assess the involvement of the SAMHD1c (120-626 aa) in 
the protein degradation, we constructed an expression plas-
mid encoding the C-terminally SAMHD1c-fused EGFP 
protein (GFP-HD) (Fig. 4A), and compared its expression 
with that of the control EGFP protein (GFP) in TE671 cells. 
As shown in Fig. 4B, the amount of the GFP-HD protein 
was increased by MG132 treatment, while the MG132 treat-
ment did not significantly affect the GFP protein abundance. 
Our results clearly demonstrated that the SAMHD1c region 
has the ability to lead not only SAMHD1 but also a heter-







Figure 2. The SAMHD1c protein is degraded in the proteasome, and the SAMHD1n inhibits the 
degradation. (A) Schematic representations of SAMHD1 and its truncated mutants are indicated. SAMHD1 
consists of the sterile-α motif (SAM) domain (aa 45-110) and the hydrolysis (HD) domain (aa 164-319). The 
SAMHD1n deletion mutant contains amino acid residues 1-119. The SAMHD1c mutant contains amino acid 
residues 120-626. Each plasmid encodes a C-terminally HA-tagged protein. Vectors encoding SAMHD1(1-626 
aa), SAMHD1n (1-119 aa), and SAMHD1c (120-626 aa) were transfected into (B) U937 cells, followed by 
PMA untreatment or treatment for overnight, and into (C) TE671 cells, followed by MG132 untreatement or 
treatement for overnight. The samples were analyzed by WB, using anti-HA and anti-β-actin antibodies, in 
which β-actin was used as a loading control (B and C). Relative levels of each protein compared to β-actin are 
shown above the lane numbers (C). Data are representative of similar results from two independent experi-
ments. 
Figure 3. HeLa cells were untreated or treated with MG132 for 
overnight, followed by SDS-PAGE and WB.  Each sample was 
analyzed with anti-HA and anti-β-actin antibodies.  Data is a rep-
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　The SAMHD1 N-terminal region protects full-length 
SAMHD1 from protesome-dependent degradation. To 
assess the role of the SAMHD1n in protein stabilization, we 
constructed an expression plasmid encoding an N-terminal-
ly SAMHD1n-fused, C-terminally Myc-tagged APOBEC3G 
protein (SA3G) (Fig. 5A). Human APOBEC3G (A3G) is de-
graded in the proteasome by the SIV or HIV-1 accessory 
protein, Vif [25,26]. The SA3G and A3G expression plas-
mids were co-transfected together with the Vif or control 
pcDNA3.1 expression plasmid into TE671 cells. As shown 
in Fig. 5B, similar levels of the SA3G and A3G proteins 
were detected without Vif. The Vif co-expression decreased 
the A3G protein expression (28-fold), while, the SA3G pro-
tein was slightly but steadily resistant to the Vif-mediated 
protesomal degradation (8-fold), indicating that the SAM-
HD1n can protect the heterologous A3G protein from pro-
teasomal degradation in TE671 cells. 
　The SAMHD1 N-terminal region is critical for SAM-
HD1 stabilization in differentiated U937 cells. To know if 
the SAMHD1n-mediated protein stabilization is correlated 
to cell-type specific HIV-1 infection restriction ability of 
SAMHD1, the same experiment was performed on U937 
cells, followed by PMA treatment. As in TE671 cells, the 
addition of Vif dramatically reduced the amount of the A3G 
protein (70-fold), while that of the SA3G protein was hardly 
affected (3-fold), indicating that SA3G was highly resistant 
to Vif-mediated proteasomal degradation in U937 cells (Fig. 
5C). Although the SAMHD1n protected the A3G protein 
from Vif-mediated proteasomal degradation in TE671 cells, 
Vif still reduced the amount of the SA3G protein signifi-
cantly in this cell line. Thus, these results suggested that the 
ability of the SAMHD1n to confer resistance to proteasome-
dependent degradation was more prominent in U937 cells 
than in TE671 cells. 
　Trans-expression of SAM mutant protein does not af-
fect SAMHD1 protein stability.
　In addition, we tested if the trans-expressed SAMHD1n 
can rescue protein from the degradation. SAMHD1n ex-
pression plasmid was transfected into TE671 cells, together 
with the full-length SAMHD1 or SAMHD1c expression 
plasmid. As a result, neither the SAMHD1 nor SAMHD1c 
protein abundance was elevated by the trans-expression of 
Figure 4. The SAMHD1c leads to proteasome-dependent degradation of a heterologous 
protein. (A) Schematic representations of GFP and C-terminally SAMHD1c fused GFP 
proteins are indicated. GFP and SAMHD1c were fused at the XhoI site. (B) GFP and GFP-
SAMHD1c were transfected into TE671 cells. After 24 hrs of culture, the transfected cells 
were treated with MG132, and then further cultured for 24 hrs. Whole cell lysates were col-
lected, fractionated by SDS-PAGE and analyzed by WB. The expression of the GFP and GFP-
SAMHD1c proteins was analyzed with an anti-GFP antibody. β-actin was used as a loading 
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SAMHD1n protein (Fig. 6), indicating that only the cis-




　Our study is the first report showing that the HD domain-
containing C-terminal region of SAMHD1 is responsible 
for the proteasome-dependent degradation of SAMHD1 in 
the absence of Vpx, whereas the SAM domain-containing 
N-terminal region is critical for the stability of the full-
length SAMHD1 protein. SAMHD1 can restrict HIV-1 vec-
tor infection in PMA-differentiated U937 macrophage and 
TE671 rhabdomyosarcoma cells, but not in HeLa cells. The 
SAMHD1n-mediated stabilization of the SAMHD1 protein 
occurs more efficiently in differentiated U937 cells than in 
TE671 cells, correlated to the degree of restriction of these 
cells. Interestingly, while we were preparing this manu-
script, White et al. and Cribier et al. showed that the phos-
Figure 5. The SAMHD1n can protect a heterologous protein from proteasome-dependent degradation in TE671 
and PMA-differentiated U937 macrophage cells. (A) Schematic representations of the A3G and N-terminally SAMH-
D1n-fused A3G (SA3G) proteins are indicated. SAMHD1n and A3G were fused at the SalI site. Each plasmid encodes a 
C-terminally Myc-tagged protein. (B) TE671 cells and (C) U937 cells were co-transfected with A3G and SA3G, together 
with pcDNA3.1 or Vif. U937 cells were treated with PMA after the transfection. The expression of the A3G and SA3G 
proteins was analyzed by WB, using the anti-Myc antibody. β-actin was used as a loading control and relative levels of 





Figure 6. Trans expression of SAMHD1n mutant protein does 
not affect SAMHD1 protein stability. TE671 cells were trans-
fected with a vector encoding the full-length SAMHD1 (left 
panel) or the SAMHD1c mutant (right panel) protein, together 
with pcDNA3.1 or the SAMHD1n mutant. Cell lysates from the 
transfected cells were analyzed by WB. Data are representative of 
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phorylation of SAMHD1 determines the cell-type specific 
restriction of HIV-1 infection by SAMHD1 [27,28]. They 
proposed that the phosphorylation of SAMHD1 C-terminal 
at T592 aa regulates the retroviral restriction ability of 
SAMHD1. The close relationship between phosphorylation 
and ubiquitination has been well understood [29]. It is high-
ly speculated that the ubiquitination of the SAMHD1c is 
also regulated by the phosphorylation of this region. Never-
theless, our study suggests that the stabilization of SAM-
HD1 by the SAMHD1n contributes to its restriction of HIV-
1 infection.
　Previous report has shown that N-terminal region-deleted 
SAMHD1 protein (112-626 aa) could still restrict HIV-1 
vector infection in PMA-differentiated U937 cells [15], sug-
gesting that the SAM domain containing N-terminal region 
is dispensable for the HIV-1 restrictive function of SAM-
HD1. However, it is still possible that the SAM domain par-
ticipates in the infection restriction, since a SAM domain 
(45-110)-deleted SAMHD1 mutant protein reportedly fails 
to restrict HIV-1 infection in PMA-differentiated U937 
cells, and its abundance is lower than that of the wild type 
SAMHD1 [15]. Several reports have shown that the amounts 
of N-terminally truncated SAMHD1 proteins are lower than 
that of the full-length protein [9,10,11,15,23]. In addition, re-
cent report revealed that the SAMHD1 N-terminal region 
(1-118) is necessary to maximize the dGTP triphosphatase 
and nuclease activities, and indispensable for nucleic acid 
and viral genome binding activities of SAMHD1 [14]. To-
gether, these reports suggested that the SAM domain is nec-
essary for the SAMHD1-mediated restriction of HIV-1 in-
fection and protein stability.  
　Notably, the SA3G protein was remarkably resistant to 
the Vif-induced degradation in differentiated U937 cells. 
The tertiary structure of SA3G is considered to have minor 
or no effect to the A3G interaction with Vif by the SAMH-
D1n fusion, because the amount of the SA3G protein was 
significantly reduced by Vif in TE671 cells. To further sup-
port the involvement of the SAM domain in the protein pro-
tection from proteasome-dependent degradation, Park et al. 
[30] reported an interesting feature about the SAM domain 
of the tyrosine kinase-type A2 receptor (EPHA2) protein: 
the group showed that the SAM domain of the EPHA2 pro-
tein plays a critical role in its stability, by modulating the 
proteasome-dependent process. The SAMHD1 SAM do-
main shares 40% similarity and 16% identity with that of 
EPHA2 (Phyre2 program). The SAM domain is responsible 
for protein-protein or protein-RNA interactions [31]. There-
fore, an interaction between the SAMHD1n and an un-
known cellular factor may stabilize the SAMHD1 protein.
　Vpx at its N-terminal region forms a complex with SAM-
HD1 C-terminal region (606-626 aa) and loads it to the 
CRL4DCAF1 ubiquitin E3 ligase, followed by proteasomal 
degradation[11]. However, we have shown that the SAMH-
D1c contains a motif that leads SAMHD1 into proteasome-
dependent degradation, in the absence of Vpx. The SAM-
HD1 protein may be stabilized by an intramolecular 
interaction between the SAMHD1n and SAMHD1c regions. 
Vpx may compete with the SAMHD1n, and induce the deg-
radation of the full-length SAMHD1 protein. Identifying 
the relationship between these core domain containing re-
gions and the Vpx is our next target of interest in parallel 
with disclosing the contribution of SAMHD1c phosphoryla-
tion to the full-length SAMHD1 stability. 
　In summary, the HD domain-containing C-terminal re-
gion leads the SAMHD1 protein to proteasomal degrada-
tion. The SAM domain-containing N-terminal region stabi-
lizes the SAMHD1 protein efficiently in differentiated U937 
cells and in TE671 cells, in which SAMHD1-mediated HIV-
1 infection restrictions were observed, suggesting that the 
SAM-mediated stabilization of the SAMHD1 protein is im-
portant for its anti-virus activity. Further studies are re-
quired to understand the mechanism by which the SAMH-
D1n stabilizes the SAMHD1 protein. 
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